Med. Pro Praxi 2007; 4(11): 454-457

Novinky v léčbě osteoporózy

MUDr. Tomáš Hála
Ústav zdravotnických studií, Univerzita Pardubice, Pardubice

Důsledkem osteoporózy jsou zlomeniny, zejména obratlů a kyčle. Tyto zlomeniny významně zhoršují kvalitu života a zkracují jeho délku. V současné době máme k dispozici paletu účinných léků v terapii osteoporózy a další nové léky jsou ve fázi výzkumu. Denosumab, glucagon-like-peptide-2, inhibitory katepsinu K, orální forma kalcitoninu a látky ovlivňující kalcium-sensing receptor mohou být v budoucnu účinnými léky v boji proti osteoporóze. Jejich efekt je navíc zprostředkován novými mechanizmy účinku.

Keywords: osteoporóza, denosumab, glucagon-like-peptide-2, inhibitory katepsinu K, orální forma kalcitoninu a látky ovlivnující kalcium-sensing receptor

Published: December 19, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hála T. Novinky v léčbě osteoporózy. Med. praxi. 2007;4(11):454-457.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Abrahamsen B, Teng AY. Technology evaluation: denosumab, Amgen. Curr Opin Mol Ther 2005; 7: 604-610.
    2. Boushey RP, Yusta B, Drucker DJ. Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor. Cancer Res 2001; 61: 687-693. Go to PubMed...
    3. Brown EM, Gamba G, Riccardi D et al. Cloning and characterization of an extracellular Ca (2+)sensing receptor from bovine parathyroid. Nature. 1993 Dec 9; 366 (6455): 575-580. Go to original source... Go to PubMed...
    4. Consensus development konference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993; 94: 646-650. Go to original source... Go to PubMed...
    5. Cranney A, Tuqwell P, Zytaruk N, Robinson V, Weaver B et al. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocrine Rev 2002; 23: 540-551. Go to original source... Go to PubMed...
    6. Cummings SR, Melton J III. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002; 359: 1761-1767. Go to original source... Go to PubMed...
    7. Cummings SR, Nevitt MC, Browner WS et al. Risk facrors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995; 332: 767-773. Go to original source... Go to PubMed...
    8. Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R. Anabolic actions of parathyroid hormone. Endocr Rev. 1993 Dec; 14 (6): 690-709. Go to original source... Go to PubMed...
    9. Dougall W, Chaisson M. Monoclonal antibody targeting RANKL as a therapy for cancer-induced bone diseases. Clin Calcium 2006; 16: 627-635. Go to PubMed...
    10. Fujita Y, Nakata K, Yasui N et al. Novel mutations of cathepsin K gene in patients with pycnodysostosis and their characterization. J Clin Endocrinol Metab 2000; 85: 425-431. Go to original source... Go to PubMed...
    11. Fuller K, Kirstein B, Chambers TJ. The regulation and enzymatic basis of bone resorption by human osteoclasts. Clin Sci (Lond). 2007 Jan 23; [Epub ahead of print]. Go to original source... Go to PubMed...
    12. Haderslev KV, Jeppesen PB, Hartmann B et al. Short-term administration of glucagon-like peptide-2. Effects on bone mineral density and markers of bone turnover in short-bowel patients with no colon. Scand J Gastroenterol 2002; 37: 392-398. Go to original source... Go to PubMed...
    13. Hala T, Senk F, Zivny P, Skyvarova L, Carda M. The loss of follow up after a fragility hip fractures in some regions in Czech Republic. Amsterdam International Menopause Symposium. Abstract book 2007.
    14. Hamdy NA. Osteoprotegerin as a potential therapy for osteoporosis. Curr Osteoporos Rep 2005; 3: 121-125. Go to original source... Go to PubMed...
    15. Henriksen DB, Alexandersen P, Bjarnason NH et al. Role of gastrointestinal hormones in postprandial reduction of bone resorption. J Bone Miner Res 2003; 18: 2180-2189. Go to original source... Go to PubMed...
    16. Henriksen DB, Alexandersen P, Byrjalsen I et al. Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2. Bone 2004; 34: 140-147. Go to original source... Go to PubMed...
    17. Henriksen DB, Alexandersen P, Hartmann B et al. GLP-2 Administration Attenuates Nocturnal Bone Resorption in Postmenopausal Women: A 14-Day Study. J Bone Miner Res 2005; 20 Suppl 1: CO 30. Go to PubMed...
    18. Chesnut CH 3rd, Majumdar S, Newitt DC et al. Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study. J Bone Miner Res. 2005 Sep; 20 (9): 1548-1561. Epub 2005 Apr 27. Go to original source... Go to PubMed...
    19. Chesnut CH, Silverman S, Andriano K et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with estbalished osteoporosis. The Prevent Recurrence Of Osteoporotic Fractures study. Am J Med 2000; 109: 267-276. Go to original source... Go to PubMed...
    20. Ismail AA, Cockerill W, Cooper C et al. Prevalent vertebral deformity predicts incident hip though not distal forearm fracture: result from the European prospective osteoporosis. Osteoporos Int 2001; 12: 85-90. Go to original source... Go to PubMed...
    21. Jalovaara P, Virkkunen H. Quality of life after primary hemiarthropalsty for femoral neck fracture: 6-year follow-up of 185 patients. Acta Orthop Scand 1991; 62 (3): 208-217. Go to original source... Go to PubMed...
    22. Jeppesen PB, Hartmann B, Thulesen J et al. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon Gastroenterology 2001; 120: 806-815. Go to original source... Go to PubMed...
    23. Karsdal MA, Tanko LB, Riis BJ et al. Calcitonin is involved in cartilage homeostasis: is calcitonin a treatment for OA? Osteoarthritis Cartilage 2006; 14: 617-624. Go to original source... Go to PubMed...
    24. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001; 142: 5050-5055. Go to original source... Go to PubMed...
    25. Kim TS, Tasker AS. Non-covalent cathepsin K inhibitors for the treatment of osteoporosis. Curr Top Med Chem 2006; 6: 355-360. Go to original source... Go to PubMed...
    26. Klotzbuecher CM, Ross PD, Landsman P et al. Patients with prior fracture have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Minerr Res 2000; 15: 721-739. Go to original source... Go to PubMed...
    27. Kostenuik PJ, Shalhoub V. Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. Curr Pharm Des 2001; 7: 613-635. Go to original source... Go to PubMed...
    28. Kostenuik PJ. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol 2005; 5: 618-625. Go to original source... Go to PubMed...
    29. Lacey DL, Timms E, Tan HL et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165-176. Go to original source... Go to PubMed...
    30. Lewiecki EM. RANK ligand inhibition with denosumab for the management of osteoporosis. Expert Opin Biol Ther 2006; 6: 1041-1050. Go to original source... Go to PubMed...
    31. Lindsay R, Silverman SL, Cooper C et al. Risk of new vertebral fracture in the yaer following a fracture. JAMA 2001; 285 (3): 320-323. Go to original source... Go to PubMed...
    32. Martin GR, Wallace LE, Sigalet DL. Glucagon-like peptide-2 induces intestinal adaptation in parenterally fed rats with short bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2004; 286: G964-972. Go to original source... Go to PubMed...
    33. McClung MR. Inhibition of RANKL as a treatment for osteoporosis: preclinical and early clinical studies. Curr Osteoporos Rep 2006; 4: 28-33. Go to original source... Go to PubMed...
    34. Melton LJ III, Hamer M, Ray NF et al. Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation. J Bone Miner Res 1997; 12 (1): 16-23. Go to original source... Go to PubMed...
    35. Miller LR, Shewchuk LM, Wells-Knecht K et al. Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin K. J Med Chem 2004; 47: 588-599. Go to original source... Go to PubMed...
    36. Munoz-Torres M, Alonso G, Raya MP. Calcitonin therapy in osteoporosis. Treat Endocrinol. 2004; 3: 117-132. Go to original source... Go to PubMed...
    37. Osteoporosis prevention, diagnosis and therapy. NIH konsensus statements 2000; 17 (1): 1-45. http://konsensus.nih.gov/cons/111/111_intro.htm/.
    38. Scott RB, Kirk D, MacNaughton WK, Meddings JB. GLP-2 augments the adaptive response to massive intestinal resection in rat. Am J Physiol 1998; 275: G911-921. Go to original source... Go to PubMed...
    39. Silverman SL, Azria M. The analgesic role of calcitonin following osteoporotic fracture. Osteoporosis Int 2002; 13: 858-867. Go to original source... Go to PubMed...
    40. Sondergaard BC, Wulf H, Henriksen K et al. Calcitonin directly attenuates collagen type II degradation by inhibition of matrix metalloproteinase expression and activity in articular chondrocytes. Osteoarthritis Cartilage. 2006; 14: 759-768. Go to original source... Go to PubMed...
    41. Tanko LB, Bagger YZ, Alexandersen P et al. Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover. J Bone Miner Res 2004; 19: 1531-1538. Go to original source... Go to PubMed...
    42. Tavares FX, Boncek V, Deaton DN et al. Acute effects of calcitonin nasal spray on serum Ctelopeptide of type 1 collagen (CTx) levels in elderly osteopenic women with increased bone turnover. Calcif Tissue Int. 2004 Dec; 75 (6): 477-81. Epub 2004 Sep 16. Go to original source... Go to PubMed...
    43. Walker N, Norton R, Vander Hoorn S et al. Mortality after hip fracture: regional variations in New Zealand. N Z Med J 1999; 112 (1092): 269-271. Go to PubMed...
    44. Wallis K, Walters JR, Forbes A. Review article: glucagon-like peptide 2 - current applications and future directions. Aliment Pharmacol Ther 2007; 25: 365-372. Go to original source... Go to PubMed...
    45. Washizawa N, Gu LH, Gu L, Openo KP, Jones DP, Ziegler TR. Comparative effects of glucagon-like peptide-2 (GLP-2), growth hormone (GH), and keratinocyte growth factor (KGF) on markers of gut adaptation after massive small bowel resection in rats. J Parenter Enteral Nutr 2004; 28: 399-409. Go to original source... Go to PubMed...
    46. Wasnich RD, Davis JW, Ross PD. Spine fracture risk is predicted by non-spine fractures. Osteoporos Int 1994; 4: 1-5. Go to original source... Go to PubMed...
    47. Wu GH, Chen J, Li H, Wu ZH. Effects of glucagon-like peptide 2 on the adaptation of residual small bowel in a rat model of short bowel syndrome. Zhonghua Wei Chang Wai Ke Za Zhi 2006; 9: 441-444. Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.